Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin inhibits JAK2/STAT3 signaling and restores tight junction proteins in dextran sulfate sodium-induced colitis. (A) Representative western blotting images of p-JAK2, JAK2, p-STAT3, STAT3, IL-6, occludin, ZO-1 and β-actin expression in colon tissues. Densitometric semi-quantification of the relative protein expression levels of (B) p-JAK2/β-actin, (C) JAK2/β-actin, (D) p-JAK2/JAK2, (E) p-STAT3/β-actin, (F) STAT3/β-actin, (G) p-STAT3/STAT3, (H) IL-6/β-actin, (I) occludin/β-actin and (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. control group; # P<0.05 and ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; C, control group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; IL-6, ZO-1, zona occludens-1.

Article Snippet: Membranes were subsequently incubated separately with primary antibodies for p-JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), ZO-1 (1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam), and then with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. ab6721; Abcam).

Techniques: Western Blot, Expressing, Control

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin suppresses JAK2/STAT3 activation in IL-6-stimulated Caco-2 cells with STAT3 silencing. (A) Western blot analysis of p-JAK2, JAK2, p-STAT3, STAT3, occludin and ZO-1 in Caco-2 cells under indicated treatments. (B) Validation of STAT3 knockdown efficiency: Relative STAT3 expression in cells transfected with siSTAT3 vs. siNC. ## P<0.01 vs. siNC. Densitometric semi-quantification of relative protein expression levels of (C) p-JAK2/β-actin, (D) JAK2/β-actin, (E) p-JAK2/JAK2, (F) p-STAT3/β-actin, (G) STAT3/β-actin, (H) p-STAT3/ STAT3, (I) occludin/β-actin, (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group; Δ P<0.05 and ΔΔ P<0.01 IL-6 + Nar group vs. IL-6 + Nar + siSTAT3 group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; ZO-1, zona occludens-1; si, small interfering RNA; NC, negative control.

Article Snippet: Membranes were subsequently incubated separately with primary antibodies for p-JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), ZO-1 (1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam), and then with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:5,000; cat. no. ab6721; Abcam).

Techniques: Activation Assay, Western Blot, Biomarker Discovery, Knockdown, Expressing, Transfection, Small Interfering RNA, Negative Control

Journal: The Journal of biological chemistry

Article Title: Chimeric erythropoietin-interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction.

doi: 10.1074/jbc.272.8.4993

Figure Lengend Snippet: FIG. 7. Phosphorylation of Jak1 and Jak2 kinases. Untreated cells or cells treated with Hu-IFN-g or Epo were lysed and immunoprecipi- tated (I.P.) with monoclonal anti-phosphotyrosine antibodies (anti-P-Tyr panels), polyclonal anti-Jak1 antibodies (anti-Jak1 panels) or anti-Jak2 antibodies (anti-Jak2 panels) as described under “Materials and Methods.” The cell lines are indicated on the figure and are defined in the legend to Fig. 1. Immunoprecipitates were resolved on SDS-PAGE, transferred to PVDF membranes and the blots probed with anti-Jak1 or anti-Jak2 antibodies as noted under the respective horizontal panels.

Article Snippet: Rabbit anti-Jak2 antibody (catalogue no. SC-294) and rabbit anti-Stat5 antibody (catalogue no. SC-835) were from Santa Cruz Biotechnology.

Techniques: Phospho-proteomics, SDS Page

Journal: The Journal of biological chemistry

Article Title: Chimeric erythropoietin-interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction.

doi: 10.1074/jbc.272.8.4993

Figure Lengend Snippet: FIG. 8. Schematic representation of receptor complexes. A represents the IFN-gR1 homodimer bound to IFN-g. The cytoplasmic domains of the two chains are too far apart to permit transactivation of the two Jak1 kinases. B represents the active heteromeric IFN-g receptor com- plex with two IFN-gR1 and two IFN-gR2 subunits per complex. The IFN-g ho- modimer binds to two IFN-gR1 chains, followed by its interaction with two IFN- gR2 chains. The associated Jak2 and Jak1 kinases activate one another by transphosphorylation, with subsequent phosphorylation and dimerization of Stat1a. C depicts the EpoR/gR1 ho- modimer, which, unlike the IFN-gR1 ho- modimer, permits transactivation of the two Jak1 molecules. D illustrates the structure of the heterodimer of EpoR/gR1 and EpoR/gR2, which is the putative ac- tive receptor complex.

Article Snippet: Rabbit anti-Jak2 antibody (catalogue no. SC-294) and rabbit anti-Stat5 antibody (catalogue no. SC-835) were from Santa Cruz Biotechnology.

Techniques: Phospho-proteomics

Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 3 SNORD52 mediates M2 macrophage polariza- tion and activates JAK2/ STAT6 pathway. A Following transfection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the mRNA expression of SNORD52 was detected by qRT-PCR. ****P < 0.0001 vs. OE-NC. B Following trans- fection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the protein levels of Arginase-1 and CD163 were determined through Western blotting. *P < 0.05, **P < 0.01, ***P < 0.001 vs. OE-NC. C The ratio of CD206-positive or CD163-positive cells following transfection of OE-SNORD52/ OE-NC was analyzed by flow cytometry. ***P < 0.001 vs. OE-NC. D Following transfec- tion of OE-SNORD52/OE-NC in THP-1 and U937 for 48 h, the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. OE-NC. E The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the mRNA expression of SNORD52 was detected by qRT-PCR. *P < 0.05, **P < 0.01, ***P < 0.001 vs. ASO-NC. F The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the protein levels of Arginase-1 and CD163 were determined through Western blotting. ***P < 0.001 vs. ASO-NC. G The ratio of CD206-positive or CD163-positive cells following transfection of SNORD52- ASO-1/-2 or ASO-NC was analyzed by flow cytometry. ***P < 0.001 vs. ASO-NC. (H) The IL-4 and IL-13 treated THP-1/ U937 macrophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. ASO-NC. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Transfection, Expressing, Quantitative RT-PCR, Western Blot, Flow Cytometry, Incubation

Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 5 Huh7 cells-derived exosomal SNORD52 mediates M2 macrophage polarization through activating JAK2/STAT6 pathway. A Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the levels of JAK2/STAT6 pathway-related pro- teins in receptor THP-1 macrophages were measured by Western blotting. B Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the ratio of CD206-positive or CD163-positive THP-1 macrophages was analyzed by flow cytometry. **P < 0.01, ***P < 0.001. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Derivative Assay, Co-Culture Assay, Western Blot, Flow Cytometry

Journal: Oncology reports

Article Title: Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.

doi: 10.3892/or.2017.5588

Figure Lengend Snippet: Figure 2. Silibinin downregulates the expression of Jak2/STAT3 signaling proteins in a dose- and time-dependent manner. (A) Western blot analyses showing the concentration dependent effect of silibinin in MDA‑MB‑231 cells following exposure to silibinin for 24 h. (B) Relative levels of the pSTAT3, STAT3, pJak2, and Jak2 proteins. (C) Time-dependent effect of silibinin on protein expression in MDA‑MB‑231 cells. (D) Relative expression levels of pSTAT3, STAT3, pJak2, and Jak2, measured using densitometry. These data were normalized to actin levels, and then shown as a percentage of the control. The data presented are representative of three independent experiments. Statistical analyses were conducted using the t-test (**p<0.01, ***p<0.001).

Article Snippet: An anti phosphor Jak2 antibody (Tyrosine residue 1007/1008) was purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Expressing, Western Blot, Concentration Assay, Control

Journal: Oncology reports

Article Title: Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.

doi: 10.3892/or.2017.5588

Figure Lengend Snippet: Figure 7. Schematic representation of the inhibition of invasive mechanisms provoked by silibinin in MDA‑MB‑231 cells. Silibinin inhibits Jak2 expression and phosphorylation, resulting, in turn, in the inhibition of STAT3 expression, phosphorylation, nuclear translocation, and DNA binding activity. Consequently, STAT3's down-stream targets are inhibited (including MMP2), resulting in reduced cell migration and invasion.

Article Snippet: An anti phosphor Jak2 antibody (Tyrosine residue 1007/1008) was purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Inhibition, Expressing, Phospho-proteomics, Translocation Assay, Binding Assay, Activity Assay, Migration

Journal: Medicina

Article Title: Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

doi: 10.3390/medicina58121867

Figure Lengend Snippet: Characteristics included for the study of ROR1.

Article Snippet: H. Chang (2015) [ ] , Republic of Korea , Gastric cancer , 424 , IHC , Rabbit polyclonal antibody (1:25; Abcam) , Staining > 50% , - , 0.8 (0.53–1.21) p = 0.189.

Techniques: Staining, Expressing, Fluorescence

Journal: bioRxiv

Article Title: JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells

doi: 10.1101/2025.07.07.663405

Figure Lengend Snippet: (a) Proportions of retrotransposon transcripts in the transcriptomes of single haematopoietic stem cells (HSCs) after administration of THPO (Nakamura-Ishizu et al. ). Each dot indicates the total proportion of retrotransposon transcripts in a single HSC. RNA-seq was performed 24 hours after wildtype mice were treated with a single dose of THPO or saline (control). ERV=endogenous retrovirus, LINE=long interspersed nuclear element, SINE=short interspersed nuclear element,. (b) Proportions of retrotransposon transcripts in the transcriptomes of single HSCs (ESLAMs, EPCR + , Sca-1 + , c-Kit + , CD150 + , and CD48-) from mice with and without a homozygous activating JAK2 p.V617F mutation (Kirschner et al , 192 cells). (c) Proportions of SINEs conserved in human and mice, ERV and LINE transcripts in the transcriptomes of single human HSPCs (Lin-CD34+) from MPN patients (Rodriguez-Meira et al ). JAK2 p.V617F mutational status of each cell was determined by TARGET-seq (WT, wild-type; HET, heterozygous; HOM, homozygous). All p values determined by Wilcoxon rank-sum test.

Article Snippet: Two anti-JAK2 antibodies were used – JAK2 Ab 1: JAK2 polyclonal antibody A302-178A (Bethyl laboratories); JAK2 Ab 2: Jak2 D2E12 rabbit monoclonal (Cell signalling technologies).

Techniques: RNA Sequencing, Saline, Control, Mutagenesis

Journal: bioRxiv

Article Title: JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells

doi: 10.1101/2025.07.07.663405

Figure Lengend Snippet: (a) Top row: The number of ERV, LINE, and SINE loci detected in mouse HSC RNA 24h after in vivo stimulation with THPO or vehicle control (Ctrl). Each dot represents the number of loci detected in a single HSC. Bottom row: Gene-Set Enrichment Analysis (GSEA) of the three classes of retrotransposons for the same experiment, indicating the downregulation of large numbers of retrotransposon loci. NES=Normalised enrichment score. (b) Gene-Set Enrichment Analysis of interferon-regulated genes after acute THPO treatment showing no significant changes. (c) Number of ERV, LINE, and SINE loci detected in HSC RNA from wild-type (WT) and JAK2 p.V617F homozygous mutant (V617F) mice. Each dot represents the number of loci detected in a single HSC. (d) The number of ERV, LINE and conserved SINE loci detected in RNA from human CD34+ HSPCs. JAK2 p.V617F mutational status of each cell was determined by TARGET-seq (WT, wild-type; HET, heterozygous; HOM, homozygous). All p values measuring differences in the number of loci detected were determined by Wilcoxon rank-sum test.

Article Snippet: Two anti-JAK2 antibodies were used – JAK2 Ab 1: JAK2 polyclonal antibody A302-178A (Bethyl laboratories); JAK2 Ab 2: Jak2 D2E12 rabbit monoclonal (Cell signalling technologies).

Techniques: In Vivo, Control, Mutagenesis

Journal: bioRxiv

Article Title: JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells

doi: 10.1101/2025.07.07.663405

Figure Lengend Snippet: (a) Phosphoproteomic screening for JAK1/2 dependent phosphotyrosines: Change in phosphorylation levels of tyrosines treated with JAK1/2 inhibitors TG101209 (y-axis) and Ruxolitinib (x axis) of the cell lines HEL, L1236 and TMD8. Phosphotyrosines that were reduced by at least one third by both JAK1/2 inhibitors are shown in blue, HNRNPA1 pY295 and JAK2 pY570 (positive control) are highlighted. (b) Number of phosphotyrosine residues downregulated by at least one third by both JAK1/2 inhibitors in HEL, TMD8 and/or L1236 cells. (c) Experimental setup to screen for nuclear JAK2 interacting proteins, using metabolic labelling. (d) Enrichment of JAK2 interacting proteins in HEL, TMD8 and L1236 cells. Two RIME coimmunoprecipitation experiments are shown for each cell line, using two different anti-JAK2 antibodies. Proteins enriched at least two-fold (dotted lines) by both anti-JAK2 antibodies are indicated in red. JAK2 (positive control) and HNRNPA1 are highlighted. (e) Number of nuclear proteins interacting with JAK2 in HEL, TMD8 and L1236 cells. The seven proteins enriched at least 2-fold by both anti-JAK2 antibodies in all three cell lines are listed. (f) Summary of the JAK2 interactome and JAK1/2 phosphoproteome data. In red, the JAK2 interacting proteins are shown for all three cell lines, (+) signifies enrichment by both JAK2 targeting antibodies. In blue, JAK1/2 inhibitor sensitivity of the phosphotyrosines are shown for both inhibitors and all three cell lines, (+) signifies JAK1/2-dependence of the phosphotyrosines. All phosphotyrosines downregulated by both inhibitors in the same cell line in which the protein interacts with JAK2 are shown. (g) In vitro tyrosine phosphorylation of HNRNPA1 and STAT5 peptides by purified recombinant JAK2 and SYK tyrosine kinases, measured by ELISA. (h) Relative levels of phosphotyrosine residues following THPO treatment of 293T MPL cells, measured by mass spectrometry and normalised to levels 30min post THPO exposure. (i) Detection of selected phosphotyrosine residues in primary mouse tissues by mass spectrometry, indicated by a + sign. Tissues from mice homozygous for an activating JAK2 p.V617F mutation, or age- and sex-matched wildtype control mice.

Article Snippet: Two anti-JAK2 antibodies were used – JAK2 Ab 1: JAK2 polyclonal antibody A302-178A (Bethyl laboratories); JAK2 Ab 2: Jak2 D2E12 rabbit monoclonal (Cell signalling technologies).

Techniques: Phospho-proteomics, Positive Control, Metabolic Labelling, In Vitro, Purification, Recombinant, Enzyme-linked Immunosorbent Assay, Mass Spectrometry, Mutagenesis, Control